Adaptive immune receptors recognizing CTH522

Adaptive immune receptors recognizing CTH522 refer to the specific repertoire of B-cell receptors (BCRs) and T-cell receptors (TCRs) that are activated by the CTH522 recombinant protein. CTH522 is a vaccine candidate based on the Major Outer Membrane Protein (MOMP) of Chlamydia trachomatis, engineered to include variable segments from multiple serovars to provide broad-spectrum immunity (Abraham et al., 2019, The Lancet Infectious Diseases). Upon vaccination, these receptors recognize specific epitopes on the CTH522 antigen, leading to the production of neutralizing antibodies and the activation of Th1-biased T-cell responses (Olsen et al., 2015, Vaccine). This targeted immune activation is intended to prevent Chlamydia trachomatis infection and its associated complications, such as pelvic inflammatory disease and infertility. The interaction between CTH522 and these adaptive immune receptors is the fundamental mechanism by which the vaccine candidate confers protection. Clinical trials have demonstrated that targeting these receptors with CTH522 adjuvanted with CAF01 or aluminum hydroxide is safe and induces robust immunogenicity in humans (Abraham et al., 2019, The Lancet Infectious Diseases).

Other names

CTH522-specific B-cell receptorsCTH522-specific T-cell receptorsAnti-CTH522 antibodiesMOMP-specific immune receptors

The CTH522 vaccine acts as an immunogen that binds to and activates specific B-cell receptors (BCRs) and T-cell receptors (TCRs), triggering clonal expansion and differentiation into antibody-secreting plasma cells and effector T cells to provide protection against Chlamydia trachomatis (Abraham et al., 2019, The Lancet Infectious Diseases).